Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Cepheid selected to support CHA with MRSA test solution

Cepheid : 07 April, 2008  (Application Story)
Connecticut Hospital Association (CHA) Shared Services Program has been selected Cepheid as the vendor of choice for molecular surveillance testing of Methicillin-resistant Staphylococcus aureus (MRSA) with Cepheid's GeneXpert Systems and Xpert MRSA test.
Under the terms of the agreement, which includes a minimum purchase commitment, CHA Shared Services Program will exclusively market Cepheid's GeneXpert Systems and Xpert MRSA test kits to up to 164 of its acute care member hospitals at pre-negotiated prices.

The CHA Shared Services Program membership reaches across nine states, including Connecticut, Massachusetts, Maine, Rhode Island, New Hampshire, Vermont, Illinois, Wyoming, and Iowa. Illinois state law mandates surveillance of MRSA in hospitals and four of the other states have introduced legislation to prevent and control health care associated infections.

'This agreement with the CHA Shared Services Program extends access of the GeneXpert System to 164 large and small healthcare providers,' said Rob Koska, Cepheid's senior vice president of worldwide commercial operations. 'The CHA Shared Services Program membership is comprised of hospitals ranging in size from less than 50 beds to well over 800 beds.

Cepheid is making it both technically and economically possible for institutions of any size to get the two hour turnaround time - including sample collection to delivered result - that is vital to surveillance programmes looking to reduce costly and deadly Healthcare Acquired Infections (HAIs).'

MRSA is a growing public health concern, and is cited as the leading cause of death among all HAIs. Cepheid markets Xpert MRSA, a molecular test that runs on the GeneXpert System for the rapid detection of MRSA, both essential components of hospitals' active surveillance and screening programs to reduce infection rates. The modular design of the GeneXpert System makes it suitable for hospitals with modest to high-volume testing needs, and is the only PCR-based, moderate complexity system that doesn't require highly-skilled labor.

On-demand Xpert MRSA results enables healthcare professionals to rapidly identify carriers of the potential pathogen within two hours. As recent studies published in both the Journal of the American Medical Association and the Annals of Internal Medicine demonstrate, true rapid test turnaround time is critical to enabling implementation of proper Infection control measures to reduce HAI rates and improve patient care.

'The CHA Shared Services Program is excited to make this new technology available to our membership as they continually improve their Infection control programs,' said Diane T Mase, assistant vice president, CHA Shared Services Program. 'This agreement is a part of our overall goal of consistently delivering solutions for the emerging needs of our members.'
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo